# Amgen Inc.  Share Price Target ‘$318.72’, now -.9% Downside Potential

- Link: https://www.directorstalkinterviews.com/amgen-inc.share-price-target-318.72-now.9-downside-potential/4121164743
- Published: 2024-07-12T14:47:33+01:00
- Author: Charlotte Edwards

**Amgen Inc.** with ticker code (AMGN) now have 23 market analysts covering the 
stock. The analyst consensus now points to a rating of ‘buy’. The range between 
the high target price and low target price is between $380.00 and $170.00 suggesting
an average analyst share price target price of $318.72. (at the time of writing).
Given that the stocks previous close was at $321.67 this would indicate that there
is a downside of -.9%. It’s also worth noting that there is a 50 day moving average
of $306.96 and the 200 day MA is $286.92. The company has a market cap of 174.39B.
The stock price for the company is currently $325.09 USD

 The potential market cap would be $172,790,349,334 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 46.51, revenue per share of $55.15
and a 4.88% return on assets.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures
and delivers various human therapeutics. It operates in human therapeutics segment.
The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab),
Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha(
evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb),
Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO(
blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (
adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene
laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras,
Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment
of serious illness in the areas of inflammation, oncology/hematology, bone health,
cardiovascular disease, nephrology and neuroscience.

Share on: